PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer [0.03%]
铂类化疗后或不适合顺铂患者的一线治疗中使用PD-1和PD-L1抑制剂：数十年无望之后，PD-1和PD-L1抑制剂使转移性尿路上皮癌患者的预后和总生存期得到明显改善
Irene Resch,Shahrokh F Shariat,Kilian M Gust
Irene Resch
Until recently, there were no true innovations in the management of locally advanced (aUC) and metastatic urothelial cancer (mUC) in the last three decades. Vinflunine has been approved by the EMA (European Medicines Agency) with only limit...
Elisabeth S Bergen,Rupert Bartsch
Elisabeth S Bergen
A combination of anthracyclines and taxanes remains the standard of care for neoadjuvant chemotherapy (NACT) resulting in increased breast conservation rate (BCR) and decreased recurrence rate [1]. Whether pathological complete response (pC...
Anna S Berghoff,Matthias Preusser
Anna S Berghoff
Brain metastases are a major challenge in modern oncology, as treatment options upon the diagnosis of symptomatic brain metastases are limited. Neo-angiogenesis was identified as a hallmark of brain metastasis development and inhibition usi...
Christine Beham-Schmid
Christine Beham-Schmid
Aggressive lymphomas are a heterogeneous group of malignancies reflecting clinical, biological and pathological diversity. Diffuse large B‑cell lymphoma is the most common histological subtype and therefore will constitute the key aspect i...
Leonhard Müllauer
Leonhard Müllauer
Next generation sequencing (NGS) has unravelled the genetic alterations that underlie the pathogenesis of cancer. It is now becoming integrated into routine clinical diagnostics of malignant tumours. NGS supports diagnosis, identifies thera...
Lukas Weiss,Florian Huemer,Richard Greil
Lukas Weiss
A multitude of new molecular and immunologic insights into gastrointestinal tumors have been presented at the ASCO meeting 2017; however, we have focused our update on practice-changing phase 3 trials and tried to set them into clinical per...
Bianca Radl,Brigitte Mlineritsch
Bianca Radl
At this year's ASCO annual meeting several important studies in the field of gynecological cancer were presented. Here we report a personal selection of the most interesting and clinically relevant data. ...
Rupert Bartsch,Elisabeth Bergen
Rupert Bartsch
At the 2017 ASCO Annual Meeting, several pertinent studies in the field of breast cancer were presented and some are deemed as being potentially practice changing. BrighTNess was the first phase III study to investigate the addition of carb...
Gudrun Absenger,Jasmin Terzic,Angelika Bezan
Gudrun Absenger
In the past few years there have been major changes in the treatment landscape in oncology; lung cancer is affected by those changes like almost no other solid tumor. The rise of further second- and third-line tyrosine kinase inhibitors off...
Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017 [0.03%]
2017年美国临床肿瘤学会（ASCO）年会头颈部鳞癌研究进展
Teresa Magnes,Alexander Egle,Richard Greil et al.
Teresa Magnes et al.
At the annual ASCO meeting clinically relevant data concerning the management of advanced head and neck cancer that will influence clinical practice in the future were presented. Chemoradiation with high-dose cisplatin remains the mainstay ...